Rheumatoid Arthritis

Rheumatoid Arthritis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof
May 25, 2017 - N°20170145503

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules ...
NEW Inhibitor of bruton's tyrosine kinase
May 25, 2017 - N°20170144986

Provided are a compound represented by formula (iii) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (iii), and the application of the pharmaceutical compositions as selective inreversible inhibitor of bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with ...
NEW Rituximab induction therapy followed by glatiramer acetate therapy
May 25, 2017 - N°20170143824

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The ...
NEW Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-tumor necrosis factor-alpha agents and uses thereof
Technophage, InvestigaÇÃo E Desenvolvimento Em Biotecnologia, Sa
May 18, 2017 - N°20170137510

The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against tumor necrosis factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-tumor necrosis factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for ...
Mesenchymal stromal cells for treating rheumatoid arthritis
Tigenix S.a.u.
May 18, 2017 - N°20170136065

The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stromal cells.
Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
Merck Patent Gmbh
May 18, 2017 - N°20170136048

The present invention provides novel pyrimidine and pyridine compounds according to formula (i), formula (ii), formula (iii), formula (iv) and formula (v) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited ...
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Antibody
Queen Mary University Of London
May 11, 2017 - N°20170129948

The present invention provides an antibody which comprises a variable heavy (vh) chain comprising cdr1, cdr2 and cdr3, and/or a variable light (vl) chain comprising cdr1, cdr2 and cdr3, wherein the cdrs have the same amino acid sequence as those from a complete antibody isolated from a synovial tissue sample of rheumatoid arthritis patients, as listed in tables 1 and 2 ...
Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8...
Abbvie Inc.
May 11, 2017 - N°20170129902

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Tiopronin prodrugs, pharmaceutical compositions thereof, and methods of use
Abbvie Inc.
May 11, 2017 - N°20170129867

Tiopronin prodrugs, pharmaceutical compositions comprising the tiopronin prodrugs, and methods of using tiopronin prodrugs and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including non-alcoholic steatohepatitis, wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, parkinson's disease, and huntington's disease.
2- (azaindol-2-yl) benzimidazoles as pad4 inhibitors
Abbvie Inc.
May 04, 2017 - N°20170119750

And salts thereof are pad4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
Azaindole derivative
Taiho Pharmaceutical Co., Ltd.
May 04, 2017 - N°20170119743

A method for treating rheumatoid arthritis, multiple sclerosis, or a disease involving jak3, including administering a compound of the formula (i) or a salt thereof to a subject
Selective proton coupled folate transporter and folate receptor, and garftase inhibitor compounds and methods of ...
Taiho Pharmaceutical Co., Ltd.
April 27, 2017 - N°20170114066

These compounds are useful in methods for treating cancer, selectively targeting cancerous cells via the proton coupled folate transporter, folate receptor alpha, and/or folate receptor beta pathways, inhibiting garftase in cancerous cells, and selectively targeting activated macrophages in a patient having an autoimmune disease, such as rheumatoid arthritis.
Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
Eternity Bioscience Inc.
April 27, 2017 - N°20170114063

The present disclosure provides a compound of formula (i) and the use thereof for the therapeutic treatment of human cancers including b-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Early diagnosis of autoimmune and inflammatory disorders
P3 Innovations, Llc
April 13, 2017 - N°20170102392

The disclosure relates to methods and assay that assists in the diagnosis of autoimmune and chronic inflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis by analyzing drug-responsiveness of an interferon signal in a hematological sample (e. G., blood) obtained from a human subject. The assay involves comparing the interferon signal in a control aliquot of the sample with ...
Human antibodies to human tnf-like ligand 1a (tl1a)
Regeneron Pharmaceuticals, Inc.
April 06, 2017 - N°20170096491

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e. G., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and ...
Inhibition of gliadin peptides
Alba Therapeutics Corporation
April 06, 2017 - N°20170096451

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases ...
Methods for treating osteoarthristis pain by administering a nerve growth factor antagonist and compositions containing ...
Rinat Neuroscience Corp.
March 30, 2017 - N°20170088610

The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
Nucleic acid that inhibits expression of irf5
Kyowa Hakko Kirin Co., Ltd.
March 23, 2017 - N°20170081667

The present invention provides a nucleic acid having activity to suppress expression of irf5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.
Antibodies that bind colony stimulating factor 1 receptor (csf1r)
Five Prime Therapeutics, Inc.
March 23, 2017 - N°20170081415

Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided. Polynucleotides encoding antibodies to csf1r are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to csf1r are provided. Such methods include, but are ...
Antibodies that specifically bind to tl1a
Cephalon, Inc.
March 23, 2017 - N°20170081400

Recombinantly expressed variant antibodies that have enhanced affinity for tl1a and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between tl1a and the death receptor 3 (dr3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, copd, pulmonary fibrosis, cystic fibrosis, ...
Fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof
Shanghai Celgen Bio-pharmaceutical Co., Ltd.
March 23, 2017 - N°20170081387

The present invention provides a fusion protein inhibiting taci-baff complex formation and preparation method therefor and use thereof. Specifically, the fusion protein of the present invention is of high biological activity for blocking baff/appril, and may significantly lower the serum igm concentration in normal balb/c mice as well as the serum igm and ige concentration in c57/b6 ...